Quick summary
GHRP-6 is the original growth hormone releasing peptide whose discovery led to identification of the ghrelin receptor. It produces potent GH secretion and the strongest appetite stimulation of any GHRP, along with preclinical evidence of cardio- and hepatoprotective effects.
Overview
GHRP-6 is the original and most well-characterized growth hormone releasing peptide, a synthetic hexapeptide that acts on the ghrelin receptor. It produces potent GH secretion accompanied by the most pronounced appetite stimulation of any GHRP — often described as an intense, sudden hunger surge within 15–20 minutes of injection. Widely studied in preclinical models for cytoprotective effects.
Mechanism of action
GHRP-6 is a met-enkephalin analog that acts as a full agonist at the ghrelin receptor (GHSR-1a), the same receptor activated by endogenous ghrelin. Binding activates protein kinase C (PKC) and mobilizes intracellular calcium via the inositol trisphosphate/diacylglycerol (IP3/DAG) pathway, triggering pulsatile GH release from pituitary somatotrophs. GHRP-6 also suppresses somatostatin signaling to further amplify GH output. In the hypothalamus, GHSR-1a activation stimulates neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons in the arcuate nucleus — the primary orexigenic (appetite-driving) circuit — producing hunger that is more intense than any other GHRP. Beyond GH secretion, GHRP-6 has demonstrated cytoprotective, anti-apoptotic, and anti-inflammatory effects in cardiac and hepatic tissue in preclinical models, mediated partly through CD36 receptor interactions independent of GHSR-1a.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| GH stimulation and muscle growth | subcutaneous | 100–300 mcg | 2–3 times daily | Inject on an empty stomach 3 times daily. Intense hunger within 15–20 minutes of injection is expected and users often plan meals accordingly. Commonly combined with a GHRH analog for synergistic GH release. |
| appetite stimulation / weight gain | subcutaneous | 150–300 mcg | once to twice daily pre-meal | Users seeking appetite stimulation (e.g., hardgainers or during bulking phases) may inject 30 minutes before large meals. The strong ghrelin-mimicking appetite effect is a defining feature of GHRP-6 versus other GHRPs. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
GHRP-6 was the peptide that led to the discovery of the ghrelin receptor, establishing the mechanistic foundation for the entire GHRP class. Decades of preclinical studies document GH secretagogue activity, cardiomyocyte protection, and hepatocellular cytoprotection. A notable rat model of myocardial infarction demonstrated reduced infarct size and improved cardiac function. A small human trial confirmed robust GH secretion dose-dependently. No large-scale human clinical trials for anabolic or cytoprotective indications have been completed. Community use is extensive for muscle building, injury recovery, and GH optimization.[1][2][3][4][5][6]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with GHRP-6 for synergistic effects.
Legal status
GHRP-6 was placed on the FDA Category 2 bulk drug substance list in September 2023, banning compounding pharmacy preparation in the US. Industry analysis as of February 2026 indicates GHRP-6 is among the ~5 peptides expected to remain on Category 2 (alongside GHRP-2, Melanotan II, LL-37, and PEG-MGF) due to cortisol/prolactin elevation and appetite stimulation concerns. No formal FDA update published as of April 2026.
Sourcing & access
Reclassification in progress
GHRP-6 is one of 14 peptides under FDA reclassification review. Access may be restored through licensed compounding pharmacies if reclassification is formalized. Check our regulatory timeline for the latest status.
Frequently asked questions
GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide and the original GHRP whose study led to the discovery of the ghrelin receptor. It produces potent GH release and is known for causing intense, sudden hunger within 15 to 20 minutes of injection.
GHRP-6 is a full agonist at the ghrelin receptor and strongly activates the NPY and AgRP neurons in the hypothalamus, which are the primary appetite-driving circuits. This ghrelin-mimicking effect produces hunger more intense than any other GHRP.
GHRP-6 was placed on the FDA Category 2 bulk drug substance list in September 2023. As of 2026, it is expected to remain on Category 2 due to cortisol and prolactin elevation and appetite stimulation concerns.
GHRP-6 produces stronger GH release but with significantly more side effects including intense hunger, cortisol elevation, and prolactin elevation. Ipamorelin is considered cleaner and more selective, producing moderate GH release without these additional hormonal effects.
Standard protocols use 100 to 300 mcg subcutaneously on an empty stomach 2 to 3 times daily. It is commonly combined with a GHRH analog like CJC-1295 for synergistic GH release. Users typically plan meals around the intense hunger that follows injection.
Research references
- Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in rat pituitary cellsPubMed
- Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective EffectsPubMed
- Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulationPubMed
- Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitusPubMed
- Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic levelPubMed
- Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanismsPubMed